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ABSTRACT
Objective: To determine pregnant women and new
mothers’ perception of risks in pregnancy.
Design, settings and participants: This was a
large-scale multinational survey including 9113
pregnant women and new mothers from 18 countries
in Europe, North America and Australia.
Main outcomes: Risk perception scores (0–10) for
harmful effects to the fetus were derived for:
(1) medicines (over-the-counter medicine and
prescribed medicine), (2) food substances (eggs and
blue veined cheese), (3) herbal substances (ginger
and cranberries) (4) alcohol and tobacco, and
(5) thalidomide.
Results: Overall, 80% (6453/8131) of women
perceived the risk of giving birth to a child with a birth
defect to be ≤5 of 100 births. The women rated
cranberries and ginger least harmful (mean risk
perception scores 1.1 and 1.5 of 10, respectively) and
antidepressants, alcohol, smoking and thalidomide as
most harmful (7.6, 8.6, 9.2 and 9.4 out of 10,
respectively). The perception varied with age, level of
education, pregnancy status, profession and
geographical region. Noticeably, 70% had not heard
about thalidomide, but of those who had (2692/9113),
the risk perception scores were 0.4–0.5 points lower in
women below 25 years compared to women aged
26–30 years.
Conclusions: In general, women perceived the risks
of giving birth to a child with birth defects low, but
there were substantial disparities between women’s
perceived risks and the actual risks when it comes to
over-the-counter agents against nausea and prescribed
medication. The study revealed that few women knew
of thalidomide, suggesting that the general awareness
among women of the teratogenic effects of thalidomide
is declining, but it has left a general scepticism about
safety of medication in pregnancy. This may have some
severe consequences if women are left without medical
treatments in pregnancy.
INTRODUCTION
Pregnancy is an important period in many
women’s lives and a period where they may
consider their own health as well as that of
their future child. Some women may
experience a conﬂict between the manage-
ment of the two. The thalidomide scandal
back in the early 1960s heightened the
awareness of the potential risks associated
with medicines taken in pregnancy.1
However, the guidance around prescribed
medicine is still relatively vague and some-
times without clear evidence base. For
example, the British National Formulary
(BNF) provides the following advice “Drugs
should be prescribed in pregnancy only if
the expected beneﬁt to the mother is
thought to be greater than the risk to the
fetus and all drugs should be avoided if pos-
sible during the ﬁrst trimester….” Further
the BNF advises that newer and untried
drugs should be avoided if possible. This lin-
gering uncertainty may result in many
women, despite their own need for treat-
ment, choosing not to take the medication
in pregnancy.2–7
Women also make important decisions in
pregnancy in terms of other exposures, for
example, alcohol, smoking and certain food
items. They may seek advice from different
sources depending on which services are
available,8 9 but the ﬁnal decisions are likely
to be inﬂuenced by the perceived risks, which
often may be higher than the actual risks.6 10
Thus, a Norwegian survey among 1548 preg-
nant women and new mothers suggested that
Strengths and limitations of this study
▪ First large-scale multinational survey of women’s
actual perception of risks of a range of sub-
stances in pregnancy.
▪ It is an internet survey with potential for selec-
tion bias towards the more literate population,
although internet penetration rate is high among
women of child-bearing age.
▪ The survey did not go into detailed questioning
about women’s perception of what constitute
harmful effects, but left this to the individual
women to define.
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perceived risks for antidepressants, smoking and alcohol
were on par with thalidomide.4 Likewise, a Spanish study
which examined the perceived risks associated with 14
speciﬁc medications also demonstrated that the per-
ceived risk was higher than the actual risks for all medi-
cations.6 This was the case not only for pregnant
women, but also for healthcare professionals and
medical students.6 Women’s perception of risks may vary
depending on age, self-image, history and healthcare.11–
13 Likewise, women with complications during preg-
nancy may be more aware of speciﬁc risks than women
with no complications.14
In a multinational internet-based population survey,
we further examined the perception of risks of adverse
fetal outcomes of medication, food items and other
exposures in pregnancy in women living in different
geographical regions in Europe, North America and
Australia.
METHODS
Data
This study was based on data from an international
survey of women in Europe, North America and
Australia (table 1). Hence, member countries of the
European Network of Teratology Information Services
(ENTIS), the Organisation of Teratology Information
Specialists (OTIS) in North America, MotherSafe in
Australia, and European institutions conducting public
health research were invited to act as national coordina-
tors of the project. Of these, 18 countries participated
(Australia, Austria, Canada, Croatia, Finland, France,
Iceland, Italy, Netherlands, Norway, Poland, Russia,
Serbia, Slovenia, Sweden, Switzerland, UK and USA).
The questionnaires were initially developed in
Norwegian and English; these were translated into the
other relevant languages and then rolled out via
QuestBack (http://www.questback.com/) after being
piloted in four countries in order to evaluate its compre-
hension and suitability to the national setting. The ques-
tionnaire was open to the public via utilisation of banners
on 1–4 websites, social networks and/or pregnancy
forums per country commonly visited by pregnant
women. Websites were selected on the basis of the
number of daily users. Information about recruitment
tools utilised and internet penetration rates in each par-
ticipating country are described in details elsewhere.15
The data were collected over a 2-month period for each
country in 2011–2012. The survey asked women to
provide some general demographic and pregnancy
details. Then women were asked to provide their assess-
ment of pregnancy risks in general, as well as their per-
ception of the harm of 13 substances: paracetamol,
antibiotics (eg, penicillins), antidepressants, thalidomide,
swine inﬂuenza-vaccine, over-the-counter (OTC) agents
to ﬁght nausea, ginger, cranberries, blue veined cheese,
eggs, alcohol in the ﬁrst trimester, smoking and dental
X-ray. Hence, women were asked the following questions:
▸ “Among 100 healthy women in a healthy environ-
ment, how many do you think will give birth to a
child with a birth defect?”
▸ “Here below is a list with various medicines, food and
other substances. Please indicate how harmful you
think they are for the foetus in a scale from 0 to 10,
where 0 corresponds to ‘not harmful’ and 10 to ‘very
harmful’. If you have not heard before about such
substance, tick ‘unknown substance’.”
Table 1 Characteristics of women completing the online
survey (n=9113)
N Per cent
Age (years)
15–20 294 3.2
21–25 1659 18.2
26–30 3310 36.3
31–35 2625 28.8
36–40 1036 11.4
41–55 189 2.1
Marital status
Married/cohabiting 8578 94.1
Divorced/single/other 535 5.9
Highest education completed
Primary/secondary school (8–9 years
of education)
380 4.2
High-school (11–13 years of
education)
2574 28.2
University or college 5120 56.2
Other education 1039 11.4
Work situation at the start of pregnancy
Student 798 8.8
Housewife 780 8.6
Healthcare personnel, that is,
physician, nurse or pharmacist
1236 13.6
Employed in another sector 5417 59.4
Job seeker 413 4.5
Other/unknown 469 5.1
Region
Northern Europe* 2820 30.9
Western Europe† 3201 35.1
Eastern Europe‡ 2342 25.7
North America§ 533 5.8
Australia 217 2.4
Pregnancy status
Currently pregnant 4938 54.2
New mother: child aged 0–28 weeks 2173 23.8
New mother: child aged >29 weeks 2001 22.0
Previous children
None 4602 50.5
One 3229 35.4
Two 983 10.8
More than two 299 3.3
*Finland (n=574), Iceland (n=71), Norway (n=1288), Sweden
(n=887).
†Austria (n=82), France (n=374), Italy (n=926), The Netherlands
(n=81), Switzerland (n=618), UK (n=1120).
‡Croatia (n=286), Poland (n=679), Russia (n=1008), Serbia
(n=220), Slovenia (n=149).
§Canada (n=236) USA (n=297).
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▸ For all exposures (except thalidomide), the actual
risk of congenital malformation is considered to be
less than 5%. Numeric rating scales ranging from 0
(not harmful for the foetus) to 10 (very harmful to
the foetus) were utilised. Women could also select
the option ‘unknown substance’, if applicable.
Statistical analyses
Summary of background characteristics
We summarised background characteristics of the
women who responded to the questionnaires and esti-
mated their baseline perception of giving birth to a
child with a birth defect. We then calculated the overall
median, mean and SD of the perceived risk scores for
each of the substances and by geographical regions
(Northern Europe, Western Europe, Eastern Europe,
North America, and Australia).
Grouping of the substances for further analyses
For our next analysis, our outcome variables were the risk
perception scores for the 13 substances. However, to
reduce the number of analyses, we ﬁrst explored whether
we could combine similar substances into a smaller
number of groups. We used two approaches to explore
how the 13 substances could be combined into groups of
related items. We applied an exploratory factor analysis,
but since factor analysis makes assumptions about normal-
ity and linear correlations that are likely to be violated by
the skewed data, we also used the non-parametric Mokken
scaling approach.15 The two sets of results taken together
supported a division into four groups: (1) medicines (para-
cetamol, antibiotics, antidepressants, swine ﬂu vaccine and
OTC nausea drugs); (2) herbal substances (ginger and
cranberries); (3) food substances (eggs and blue-veined
cheese); and (4) alcohol and smoking. Thalidomide and
dental X-rays did not appear to ﬁt well in any grouping
(for further details please see online supplementary
appendix 1). For each group we added together the scores
and divided this by the number of scores in the group to
keep the outcome variable on a scale from 0 to 10. We con-
ducted a separate analysis for thalidomide and the associa-
tions with sociodemographic factors as described below,
but did not examine dental X-rays further.
There are a number of missing values in our outcome
variables where the women either did not answer the ques-
tion or ticked ‘unknown substance’. Women with missing
values are excluded from the corresponding analyses—
where one or more substances contributing to a grouped
outcome are missing, the whole grouped outcome is
treated as missing. We report the number of individuals
included in each analysis (n) along with the results.
We used multilevel linear regression analyses to
examine associations between the four grouped risk per-
ception scores and maternal age, education, profession,
pregnancy details and geographical regions, with coun-
tries as the second level of analysis. We repeated these
analyses for thalidomide. A positive coefﬁcient denoted
a higher perception of risk than baseline, whereas a
negative coefﬁcient denoted a lower perception of risks.
All regression models were repeated adjusting for age
and education.
Factor analysis and Mokken scaling were carried out in
R for Windows V.2.15.016 using the ‘mokken’17 and
‘psych’ packages.18 Multilevel regression analyses were
carried out in Stata V.13.
RESULTS
In total, 9113 women from 18 countries responded to the
survey (table 1). The women were aged between 15 and
55 years, with the majority being in the age range of 26–
35 years (5935, 65%) (table 1). At the time they responded
to the questionnaire, 4938 (54%) were pregnant and the
majority were married/cohabiting (8578 (94%)); for half
of the women this was their ﬁrst child. Many of the women
had university or college degrees (5120 (56%)) and were
working at the start of the pregnancy (table 1).
In general, women perceived a low risk of giving birth
to a child with a birth defect. Thus, of the 8131 women
who responded to the question “Among 100 healthy
women in a healthy environment, how many do you
think will give birth to a child with a birth defect?”,
nearly 80% (6453/8131) perceived the risk to be less
than 5 of 100 births. Yet, 789 (10%) of the women
thought the baseline risk to be more than 10 of 100
births. The vast majority of women from Northern
Europe (2296 (88%)) perceived the risk to be less than
5 of 100 births and only 110 (4%) thought baseline risks
were more than 10 of 100 births. This was in contrast to
93/496 (19%) women in North America who thought
the risks were more than 10 of 100 births. There were
982 who did not know or did not answer the question.
Overall, the women rated cranberries and ginger least
harmful and antidepressants, alcohol, smoking and thal-
idomide as most harmful (ﬁgure 1 and table 2). For
some items there was a substantial difference between
geographical regions (ﬁgure 1). For example, mean risk
perception scores for antibiotics varied from 3.9 (95%
CI 3.5 to 4.3) for Australia to 7.1 (95% CI 7.0 to 7.2) for
Eastern Europe. Large variations were also observed for
mean risk perception scores for antidepressants; ranging
from 5.9 (95% CI 5.6 to 6.3) for Australia to 8.5 (95%
CI 8.4 to 8.6) for Eastern Europe—on par with alcohol
and not far below that for thalidomide (ﬁgure 1).
Women from Eastern Europe also perceived the risk of
swine ﬂu vaccine to be much higher than women from
any of the other geographical regions (ﬁgure 1).
Noticeably, many women did not know of thalidomide
and it was only rated by 2692/9113 (30%) women.
However, of the women who did respond to this ques-
tion, over 80% rated thalidomide 10 ‘very harmful’.
Perception of risks of OTC medicine against nausea,
prescription medicine and thalidomide
For OTC and prescription medicine, the perception of
risks was lowest among those aged 31–40 years and
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highest among those aged 21–25 years. Risk perception
was higher among women educated up to primary school
and high-school level; their estimated risk perception
scores were 0.36 (95% CI 0.14 to 0.58) and 0.30 (95% CI
0.20 to 0.40) points higher compared to women educated
up to university level (table 3). Likewise, women who had
their ﬁrst pregnancy (child) had a higher perception of
risks of these medicines, whereas women working as
health professionals had a substantially lower perception
of risks than women working in other professions
(table 3). Women from Eastern Europe had a consider-
ably higher perception of risks of OTC and prescribed
medicine than women from Northern Europe—their
estimated risk perception score was 1.57 (95% CI 0.72 to
2.41) points higher than that for women in the Northern
Europe reference category.
The estimated perception of risks for thalidomide was
higher among older women (estimated risk perception
scores were 0.31 (95% CI 0.13 to 0.50) for those
aged 36-40 years), but lower among younger women
(estimated risk perception scores were −0.51 (95% CI
−0.98 to −0.04) for those aged 15–20 years in compari-
son to women aged 26–30 years) (table 3). Individuals
with non-university education perceived thalidomide less
risky than women with education up to university
level (estimated risk perception score for women with
only primary level education was −0.44 (95% CI −0.86
to −0.03) compared to women in the university level
reference category (table 3). However, there were
no signiﬁcant differences in perception of risks for thal-
idomide in relation to profession or pregnancy status
(table 3).
Figure 1 Mean risk perception
scores for 13 individual items by
geographical region.
Table 2 Descriptive statistics for the risk perception scores of the 13 substances, ordered by mean score
Substance n Median Mean SD 95% CI for the mean
Cranberries 8369 0 1.1 1.9 (1.0 to 1.1)
Ginger 8318 0 1.5 2.3 (1.5 to 1.6)
Eggs 8860 1 2.2 2.8 (2.1 to 2.3)
Paracetamol 8849 2 2.6 2.6 (2.5 to 2.7)
Over-the-counter medicines against nausea 8038 4 3.9 2.7 (3.8 to 4.0)
Antibiotics 8811 5 5.4 3.1 (5.4 to 5.5)
Swine influenza vaccine 8077 6 6.1 3.3 (6.0 to 6.2)
Blue veined cheese (eg, Gorgonzola) 8444 7 6.2 3.3 (6.1 to 6.3)
Dental X-ray 8714 8 7.1 3.0 (7.0 to 7.2)
Antidepressants 8420 8 7.6 2.5 (7.5 to 7.6)
Alcohol during the 1st trimester 8783 10 8.6 2.3 (8.6 to 8.7)
Smoking (eg, cigarettes) 8752 10 9.2 1.7 (9.2 to 9.2)
Thalidomide 2692 10 9.4 1.7 (9.3 to 9.4)
Data from all countries combined, n=9113.
Question: Here below is a list with various medicines, food and other substances. Please indicate how harmful you think they are for the fetus
in a scale from 0 to 10, where 0 corresponds to ‘not harmful’ and 10 to ‘very harmful’. If you have not heard before about such substance, tick
‘unknown substance’. (‘Unknown substance’ responses are treated as missing values).
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Table 3 Association between age, education, profession, pregnancy status, geographical region and average risk perception scores
for the four groups of outcome variables (OTC and prescription medicines, cranberry and ginger, eggs and blue veined cheese,
Alcohol and smoking) and thalidomide
Unadjusted Adjusted*
Outcome Predictor n Coefficient 95% CI p Value Coefficient 95% CI p Value
OTC and prescription medicines (n=6945)
Age band (years) <0.001 <0.001
15–20 201 0.20 (−0.05 to 0.44) 0.02 (−0.24 to 0.27)
21–25 1223 0.14 (0.03 to 0.26) 0.07 (−0.05 to 0.19)
26–30 2546 Ref – Ref –
31–35 2012 −0.21 (−0.31 to −0.11) −0.19 (−0.29 to 0.09)
36–40 817 −0.24 (−0.38 to −0.10) −0.21 (−0.34 to 0.07)
41–55 146 −0.07 (−0.35 to 0.22) −0.04 (−0.33 to 0.24)
Education <0.001 <0.001
Primary 272 0.43 (0.21 to 0.64) 0.36 (0.14 to 0.58)
High-school 1907 0.35 (0.25 to 0.44) 0.30 (0.20 to 0.40)
University 3940 Ref – Ref –
Other 826 0.28 (0.15 to 0.41) 0.26 (0.13 to 0.39)
Health professional 1107 −0.74 (−0.85 to −0.63) <0.001 −0.71 (−0.82 to −0.60) <0.001
First pregnancy 3489 0.24 (0.16 to 0.32) <0.001 0.22 (0.14 to 0.31) <0.001
Pregnant now 3721 −0.06 (−0.14 to 0.02) 0.159 −0.07 (−0.15 to 0.02) 0.123
Regions 0.004 0.003
Europe
Northern 2129 Ref – Ref –
Western 2630 0.78 (−0.03 to 1.60) 0.81 (−0.01 to 1.62)
Eastern 1596 1.51 (0.67 to 2.36) 1.57 (0.72 to 2.41)
North America 415 0.41 (−0.68 to 1.50) 0.47 (−0.62 to 1.56)
Australia 175 −0.27 (−1.68 to 1.14) −0.18 (−1.59 to 1.22)
Thalidomide (n=2692)
Age band (years) <0.001 <0.001
15–20 52 −0.73 (−1.19 to −0.27) −0.51 (−0.98 to −0.04)
21–25 289 −0.48 (−0.70 to −0.26) −0.42 (−0.64 to −0.20)
26–30 881 Ref – Ref –
31–35 920 0.20 (0.04 to 0.35) 0.17 (0.02 to 0.32)
36–40 453 0.35 (0.16 to 0.53) 0.31 (0.13 to 0.50)
41–55 97 0.18 (−0.16 to 0.53) 0.18 (−0.17 to 0.52)
Education <0.001 <0.001
Primary 66 −0.62 (−1.03 to −0.21) −0.44 (−0.86 to −0.03)
High-school 605 −0.47 (−0.62 to −0.32) −0.36 (−0.52 to −0.20)
University 1727 Ref – Ref –
Other 294 −0.17 (−0.37 to 0.04) −0.10 (−0.31 to 0.11)
Health professional 694 0.21 (0.07 to 0.36) 0.004 0.13 (−0.02 to 0.27) 0.091
First pregnancy 1256 −0.05 (−0.18 to 0.07) 0.401 0.03 (−0.10 to 0.16) 0.615
Pregnant now 1382 −0.12 (−0.25 to 0.01) 0.061 −0.08 (−0.21 to 0.05) 0.212
Regions 0.577 0.724
Europe
Northern 708 Ref – Ref –
Western 1259 0.08 (−0.29 to 0.45) 0.07 (−0.30 to 0.43)
Eastern 443 −0.05 (−0.45 to 0.34) −0.01 (−0.40 to 0.37)
North America 186 −0.30 (−0.80 to 0.20) −0.27 (−0.77 to 0.22)
Australia 96 0.13 (−0.51 to 0.77) 0.03 (−0.61 to 0.66)
Cranberries and ginger (n=8058)
Age band (years) 0.064 0.065
15–20 258 0.19 (−0.04 to 0.43) 0.17 (−0.07 to 0.42)
21–25 1447 0.05 (−0.06 to 0.17) 0.04 (−0.07 to 0.16)
26–30 2946 Ref – Ref –
31–35 2333 0.05 (−0.05 to 0.15) 0.05 (−0.05 to 0.15)
36–40 912 0.20 (0.06 to 0.34) 0.21 (0.07 to 0.35)
41–55 162 0.18 (−0.11 to 0.48) 0.19 (−0.10 to 0.48)
Education 0.780 0.798
Primary 310 0.03 (−0.19 to 0.24) 0.01 (−0.21 to 0.24)
High-school 2202 0.05 (−0.05 to 0.15) 0.05 (−0.05 to 0.15)
Continued
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Table 3 Continued
Unadjusted Adjusted*
Outcome Predictor n Coefficient 95% CI p Value Coefficient 95% CI p Value
University 4631 Ref – Ref –
Other 915 0.00 (−0.13 to 0.14) 0.00 (−0.13 to 0.14)
Health professional 1124 0.08 (−0.03 to 0.20) 0.165 0.10 (−0.02 to 0.22) 0.102
First pregnancy 4066 0.04 (−0.04 to 0.13) 0.282 0.06 (−0.02 to 0.15) 0.139
Pregnant now 4353 −0.03 (−0.11 to 0.05) 0.510 −0.02 (−0.10 to 0.06) 0.651
Regions 0.450 0.461
Europe
Northern 2584 Ref – Ref –
Western 2719 0.29 (−0.27 to 0.85) 0.27 (−0.28 to 0.83)
Eastern 2076 <0.01 (−0.58 to 0.58) 0.01 (0.57 to 0.58)
North America 473 −0.12 (−0.86 to 0.63) −0.12 (−0.86 to 0.62)
Australia 206 −0.50 (−1.46 to 0.47) −0.52 (−1.48 to 0.44)
Egg and blue veined cheese (n=8339)
Age band (years) <0.001 0.002
15–20 243 −0.09 (−0.39 to 0.22) −0.15 (−0.46 to 0.17)
21–25 1464 0.09 (−0.06 to 0.23) 0.06 (−0.08 to 0.21)
26–30 3034 Ref – Ref –
31–35 2456 −0.14 (−0.26 to −0.01) −0.13 (−0.26 to −0.01)
36–40 970 −0.13 (−0.30 to 0.04) −0.12 (−0.29 to 0.05)
41–55 172 −0.66 (−1.02 to −0.30) −0.66 (−1.01 to −0.30)
Education 0.033 0.101
Primary 319 0.11 (−0.15 to 0.38) 0.10 (−0.18 to 0.37)
High-school 2318 0.13 (0.01 to 0.25) 0.10 (−0.02 to 0.22)
University 4751 Ref – Ref –
Other 951 0.20 (0.04 to 0.37) 0.19 (0.02 to 0.36)
Health professional 1169 −0.06 (−0.20 to 0.09) 0.452 −0.05 (−0.19 to 0.10) 0.545
First pregnancy 4219 0.29 (0.19 to 0.39) <0.001 0.28 (0.17 to 0.39) <0.001
Pregnant now 4497 0.14 (0.04 to 0.25) 0.006 0.13 (0.03 to 0.24) 0.011
Regions 0.010 0.008
Europe
Northern 2654 Ref Ref
Western 2993 0.81 (0.06 to 1.56) 0.83 (0.09 to 1.58)
Eastern 2035 −0.22 (−1.00 to 0.55) −0.20 (−0.97 to 0.57)
North America 446 −0.47 (−1.47 to 0.53) −0.44 (−1.44 to 0.55)
Australia 211 0.88 (−0.41 to 2.18) 0.94 (−0.35 to 2.22)
Alcohol and smoking (n=8701)
Age band (years) 0.003 0.005
15–20 278 −0.27 (−0.48 to −0.06) −0.25 (−0.47 to −0.03)
21–25 1583 −0.08 (−0.19 to 0.02) −0.08 (−0.19 to 0.03)
26–30 3161 Ref – Ref –
31–35 2509 −0.14 (−0.23 to −0.04) −0.14 (−0.23 to −0.05)
36–40 988 −0.11 (−0.24 to 0.01) −0.12 (−0.24 to 0.01)
41–55 182 −0.37 (−0.63 to −0.11) −0.37 (−0.63 to −0.11)
Education 0.542 0.694
Primary 358 0.13 (−0.32 to 0.06) 0.10 (−0.30 to 0.09)
High-school 2432 0.01 (−0.09 to 0.08) 0.00 (−0.09 to 0.09)
University 4912 Ref – Ref –
Other 999 0.03 (−0.10 to 0.15) 0.03 (−0.09 to 0.15)
Health professional 1188 0.10 (−0.01 to 0.21) 0.072 0.09 (−0.02 to 0.20) 0.114
First pregnancy 4382 −0.02 (−0.09 to 0.06) 0.637 −0.03 (−0.11 to 0.04) 0.403
Pregnant now 4702 −0.04 (−0.11 to 0.04) 0.347 −0.04 (−0.12 to 0.03) 0.272
Regions 0.284 0.274
Europe
Northern 2699 Ref – Ref –
Western 3047 −0.11 (−0.48 to 0.26) −0.10 (−0.46 to 0.27)
Eastern 2261 −0.19 (0.57 to 0.19) −0.20 (0.58 to 0.18)
North America 485 −0.32 (−0.82 to 0.18) −0.32 (−0.81 to 0.18)
Australia 212 −0.68 (−1.33 to −0.03) −0.67 (−1.31 to −0.02)
Significant findings are marked in bold.
*Adjusted analyses were all adjusted for age and education.
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Risk perception of selected food items
For eggs and blue veined cheese, those aged 31–35 and
41–55 years had a lower perception of risks than women
aged 26–30 years (table 3); the estimated risk perception
score for women aged 41–55 years was −0.66 (95% CI
−1.01 to −0.30) compared to women in the 26–30 years
reference category. Women from Western Europe had a
higher perception of risks than women from Northern
Europe, and so did women who were currently pregnant
and pregnant with their ﬁrst child. For cranberry and
ginger, there were no differences associated with age,
education, pregnancy status or geographical region
(table 3).
Alcohol and smoking
For alcohol and smoking, the youngest (15–20 years)
and the oldest (41–55 years) women perceived these
substances less risky relative to women aged 26–30 years
(table 3). There were no differences in perception of
risks associated with education, pregnancy status or geo-
graphical region.
DISCUSSION
Summary of main findings
This is the ﬁrst large scale multinational study of
women’s perception of risks on a range of substances
taken during pregnancy. Overall, perceived risk of giving
birth to a child with a birth defect was low, but there
were variations between geographical regions. Women
rated antidepressants, alcohol, smoking and thalidomide
the most harmful, and cranberries and ginger as the
least harmful. There were large individual and geo-
graphical variations in the perception of risks of OTC
and prescribed medication such as antibiotics, swine ﬂu
vaccine and antidepressants. Women from Eastern
Europe and women of lower ages, less education and
ﬁrst pregnancy perceived the risks to be highest. For
thalidomide, associations with age and education were
reversed.
Comparisons with other studies
Perception of risks of OTC, prescribed medication and
thalidomide
The US Food and Drug Administration has developed a
rule set to deﬁne teratogenic medicines based on evi-
dence from animal and human studies. In general, very
few medicines are considered teratogenic.19
Nevertheless, our study suggests that women across
Europe, North America and Australia have severe con-
cerns about the safety of many medicines. Women from
Eastern Europe reported a lower usage of OTC and pre-
scribed medicines, but a higher usage of herbal remed-
ies compared to women from other geographical
regions.20 21 This may represent a general scepticism to
conventional prescribed medication among Eastern
European women. Our ﬁndings that risk perceptions of
OTC and prescribed medication were lower with
increasing age, higher level of education and for women
working in health professions may reﬂect women’s
access to information and experience.4
Although we found a high level of agreement between
women and geographical regions on the potential
harmful effects of thalidomide, it was rather surprising
that only 30% reported on this item in the survey.
Overall, our ﬁndings suggest that the general awareness
among women of the teratogenic effects of thalidomide
is declining, but that the thalidomide scandal1 has left a
legacy of general scepticism about safety of medication
in pregnancy. This scepticism may have been fuelled by
many observational studies in recent years on adverse
effects of medicines in pregnancy, in particular antide-
pressants.22–24 Although the evidence is conﬂicting and
many studies lack the ability to control for potential con-
founding factors,25–27 the uncertainty about the adverse
effects may translate into a general disbelief or distrust
in the safety of medication. Hence, studies suggest that
if the information is conﬂicting many women choose
not to take the medication.4 28
Risk perception of selected food items and herbal remedies
Women are generally advised not to consume blue
veined cheese and uncooked eggs in pregnancy due to
the risks of listeria and salmonella infections.29 We
observed that women who were pregnant at the time of
the survey or who experienced their ﬁrst pregnancy per-
ceived the risks to be highest. These women may be the
most alert to such advice and therefore, perceived the
risks to be higher. Women in Western Europe, in particu-
lar, were concerned about the safety of these items. This
may be associated with a higher consumption and/or
prevalence of these infections in Western Europe, but
may also represent differences in public health commu-
nication. The ginger and cranberry are commonly used
herbal remedies in pregnancy,20 21 and our ﬁndings that
women perceived these to be safe are in line with a
more general perception of herbal products being safe
in pregnancy, although the evidence base for herbal
remedies is often poor.21 30
Risk perception of alcohol and tobacco
Our ﬁndings that the alcohol and smoking were per-
ceived to carry high risks in pregnancy is similar to ﬁnd-
ings of other studies.4 31 However, it was noticeable that
the very youngest and oldest women perceived smoking
and alcohol to be less risky. Both substances are consid-
ered harmful to the unborn child although there are
still debates about whether there is a safe threshold for
drinking alcohol during pregnancy. A small qualitative
study revealed that women found information and
advice about safe levels of drinking in pregnancy confus-
ing, and lacking in evidence and detail.32
Strength and limitations
This is the ﬁrst large-scale multinational survey of
women’s actual perception of risks of a range of
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substances in pregnancy. A major strength of the study is
the large numbers of participants from countries across
Europe, North America and Australia. This made it pos-
sible to conduct cross-regional comparisons of the per-
ceived risks and enable generalisation of ﬁndings on
larger geographical scales.
Internet surveys are often criticised for not having a stan-
dardised sampling frame and the potential for selection
bias towards the more literate population.33 Yet, the inter-
net penetration rate is high among women in this study
population and a comparison with the population of
women giving birth in each of the participating countries
suggests that the study samples were roughly similar (see
web appendices20). However, we adjusted all our analyses
for age and education to take into account regional differ-
ences. Also, women who took part in the survey may have
been women who were more alert to adverse birth effects
for one reason or another. Hence, our survey may overesti-
mate the perception of risks among the general popula-
tion of women in childbearing age.
Our survey did not go into detailed questioning about
women’s perception of what constitute harmful effects,
but left this to the individual women to deﬁne. It is
likely, however, that many women may have interpreted
our question broadly and considered factors such as con-
genital anomalies, still birth, preterm birth, low birth
weight, growth retardation of the fetus and developmen-
tal delays in totality. To further disentangle women’s
concept of risks, more in-depth qualitative research may
be required as has been done by Heaman et al.11
Clinical implications
This study reveals substantial disparity between women’s
perceived risks and the actual risks when it comes to
OTC agents and prescribed medication. As a conse-
quence, some women are likely to be left without
medical treatments in pregnancy, which may have detri-
mental consequences. For example, pyelonephritis fol-
lowing untreated urinary tract infections can result in
signiﬁcant maternal and fetal morbidity and mortality.34
Likewise, it is well recognised that prior depression is a
risk factor for postnatal depression and untreated
depression might have important consequences for
pregnancy outcomes.35 36 Further, important clinical
implications arise when women who take medication
before their pregnancy was known perceive these medi-
cations to be teratogenic. They may be left with a high
level of anxiety about damage done to the unborn
child, and some women in such situation might even
seek to terminate the pregnancy of otherwise wanted
children.37 38 However, research has demonstrated that
counselling and advice about the risks may prevent
unjustiﬁed termination of many pregnancies.10 38–40 Our
study highlighted the regional and sociodemographic
differences in risk perceptions. For example, we found
that women in Eastern Europe on average rated OTC
and prescription medicines 1.57 (95% CI 0.72 to 2.41)
points higher than women in Northern Europe. On a
scale from 0 to 10, this implies a substantial regional dif-
ference in risk perception. The effects of other sociode-
mographic characteristics on risk perception were less
stark. However, we noticed that profession, education,
age and parity had an impact on women’s risk percep-
tion. For example, women in their ﬁrst pregnancy on
average rated OTC and prescription medicines 0.22
(95% CI 0.14 to 0.31) points higher than other women.
This suggests that there is a need to tailor and adapt
future communication of risks and beneﬁts to speciﬁc
groups of women and geographical regions.
Our study suggests that there is a need to raise the
awareness of how risks and beneﬁts of medicine are
communicated and perceived. General practitioners
(family doctors), pharmacists, midwives, nurses and
other healthcare professionals may have a pivotal role in
advising women on potential risks and beneﬁts of pre-
scribed medicine and other items in pregnancy.4 The
language and the communication of risks may be para-
mount to women’s decision on whether to stop or con-
tinue medication in pregnancy.41 We should also be
aware that while much research focuses on speciﬁc
adverse birth outcomes, in clinical practice women may
not distinguish between these outcomes, their preva-
lence and severity.
CONCLUSION
This study suggests that women perceive the risks of
giving birth to a child with birth defects to be low, but
demonstrated a substantial disparity between women’s
perceived risks and the actual risks when it comes to
OTC agents and prescribed medication. The study
revealed that few women now know of thalidomide, sug-
gesting that the general awareness among women of the
teratogenic effects of thalidomide is declining. However,
the past thalidomide scandal has left behind a general
scepticism about safety of medication in pregnancy and
this may have some severe consequences.
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